Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVF-HER-2(628-647)-CRL 1005
- Development stage
- Phase 1
- Lead developer
- National Cancer Institute
- Modality
- Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous (based On Typical Administration Route For Peptide Vaccines; Not Explicitly Stated But Inferred From Similar Studies)
01
Overview
MVF-HER-2(628-647)-CRL 1005 is a peptide-based therapeutic cancer vaccine designed to induce an immune response against the HER2 (Receptor tyrosine-protein kinase erbB-2) antigen, which is overexpressed in certain cancers such as breast and lung cancer. The vaccine consists of a synthetic peptide corresponding to amino acids 628–647 of the HER2 protein, conjugated with CRL 1005 copolymer as an adjuvant to enhance immunogenicity. Its mechanism involves antagonizing HER2 by stimulating the production of anti-HER2 antibodies, aiming to target and destroy tumor cells expressing this receptor. The drug was developed by the National Cancer Institute and has been studied primarily for metastatic or recurrent cancers in early-phase clinical trials[1][3][7].
- Other names
- MVF-HER-2(628-647)-CRL 1005 vaccine(NCI)
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on MVF-HER-2(628-647)-CRL 1005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVF-HER-2(628-647)-CRL 1005.